







Supplementary Figure 1. Locomotor activity is not altered by sCPP or OTR-A. **a**, distance travelled is not different between groups (saline injected, pre 3116 ± 262 , post 2865 ± 215 , $n = 18$ animals, $p = 0.450$; OTR-A injected, pre 2862 ± 179 , post 2936 ± 354 , $n = 15$ animals, $p = 0.848$). **b**, ambulatory time is not different between groups (saline injected, pre 92 ± 7 , post 90 ± 89 , $n = 18$ animals, $p = 0.830$; OTR-A injected, pre 85 ± 6 , post 89 ± 9 , $n = 15$ animals, $p = 0.687$). **c**, ambulatory counts are not different between groups (saline injected, pre 1421 ± 184 , post 1330 ± 142 , $n = 18$ animals, $p = 0.688$; OTR-A injected, pre 1238 ± 122 , post 1361 ± 232 , $n = 15$ animals, $p = 0.630$). **d**, time stereotypic is not different between groups (saline injected, pre 397 ± 10 , post 383 ± 15 , $n = 18$ animals, $p = 0.417$; OTR-A injected, pre 402 ± 6 , post 383 ± 11 , $n = 13$ animals, $p = 0.111$). **e**, stereotypic counts are not different between groups (saline injected, pre 5362 ± 210 , post 5226 ± 275 , $n = 18$ animals, $p = 0.689$; OTR-A injected, pre 5453 ± 141 , post 5133 ± 192 , $n = 13$ animals, $p = 0.174$). **f**, resting time is not different between groups (saline injected, pre 1308 ± 14 , post 1284 ± 36 , $n = 18$ animals, $p = 0.532$; OTR-A injected, pre 1307 ± 12 , post 1326 ± 18 , $n = 15$ animals, $p = 0.368$). **g**, vertical counts are not different between groups (saline injected, pre 220 ± 18 , post 200 ± 22 , $n = 18$ animals, $p = 0.466$; OTR-A injected, pre 217 ± 20 , post 197 ± 38 , $n = 11$ animals, $p = 0.628$). **h**, vertical time is not different between groups (saline injected, pre 138 ± 11 , post 123 ± 11 , $n = 18$ animals, $p = 0.346$; OTR-A injected, pre 145 ± 13 , post 127 ± 17 , $n = 11$ animals, $p = 0.384$). **i**, number of transitions are not different between groups (saline injected, pre 85 ± 7 , post 74 ± 8 , $n = 18$ animals, $p = 0.306$; OTR-A injected, pre 81 ± 12 , post 87 ± 19 , $n = 15$ animals, $p = 0.759$). Summary data are presented as mean $\pm$ s.e.m. (* $P < 0.05$).




Supplementary Figure 2. Cocaine conditioned place preference (cCPP) does not require OT. **a**, Experimental time course for cocaine CPP. **b-c**, Individual (top) and average (bottom) responses in i.p. saline injected (**b**), versus i.p. OTR-A injected (**c**) animals. Both i.p. saline and i.p. OTR-A injected animals, spend more time in the cocaine context following conditioning (i.p. saline, pre 903 ± 43 , post 1042 ± 54 , $n = 34$ animals, $p = 0.034$ paired t-test; i.p. OTR-A, pre 863 ± 46 , post 1011 ± 47 , $n = 32$ animals, $p = 0.007$ paired t-test). **d**, Comparisons between i.p. saline versus i.p. OTR-A treated animals reveals no difference in normalized cocaine preference and subtracted cocaine preference in OTR-A treated animals (normalized saline 1.225 ± 0.079 , OTR-A 1.245 ± 0.074 , $p = 0.906$ unpaired t-test; subtracted saline 0.154 ± 0.069 , OTR-A 0.165 ± 0.057 , $p = 0.857$ unpaired t-test). Summary data are presented as mean $\pm$ s.e.m (* $P < 0.05$).




Supplementary Figure 3. Andalman reverse microdialysis probes. a, Schematic of Andalman probe for reverse microdialysis experiments in Fig. 1f-i and 5l-o. **b,** Post-hoc confirmation of probe placement and competency.




Supplementary Figure 4. OT expressing neurons in the paraventricular nucleus (PVN) send projections to the NAc. **a**, Diagram illustrating the injection of RbV-GFP into the NAc, followed by antibody labeling of OT producing neurons in the PVN. **b**, Localization and expression of RbV-GFP in the NAc (scale bars 200 μ m). **c-f**, Low magnification (**c**, scale bar 100 μ m) and high magnification (**d-f**, scale bars 20 μ m) images of PVN cells that have been retrogradely labeled by RbV-GFP taken up by presynaptic terminals in the NAc (green, left panels) and labeled by ant-OT-np antibody (red, center panels). Co-localization (merged right panels) indicates oxytocinergic neurons that project to the NAc; arrowheads highlight individual cells that show co-localization. (Nucleus accumbens core, NAcc; nucleus accumbens shell, AcbSh; anterior commissure, aca; caudate putamen, CPu; third ventricle, 3V; paraventricular nucleus of the hypothalamus, PVN)




Supplementary Figure 5. OT expressing neurons in the Supraoptic Nucleus (SON) do not send projections to the NAc. **a**, Diagram illustrating the injection of RbV-GFP into the NAc, followed by antibody labeling of OT producing neurons in the SON. **b**, high magnification (scale bars 20 μm) images of SON cells that have been retrogradely labeled by RbV-GFP taken up by presynaptic terminals in the NAc (green, left panels) or labeled by ant-OT-np antibody (red, center panels). Absence of co-localization (merged right panels) indicates oxytocinergic neurons do not project to the NAc.




Supplementary Figure 6. Increased magnitude of OT-LTD in both D1 and D2 receptor expressing MSN following isolation conditioning. **a-h**, Representative traces (**a,d,g**), summary time course (**b,e,h**), and average post-treatment magnitude comparisons (**c,f,i**) reveal that the magnitude of OT-LTD is significantly increased in both D1 (**a-c**) and D2 (**d-f**) cells from isolation versus socially reared animals (D1 isolation, 0.379 ± 0.090 , $n = 6$ cells and D1 social, 0.756 ± 0.078 , $n = 9$ cells, $p = 0.00524$ unpaired t-test; D2 isolation, 0.386 ± 0.129 , $n = 5$ and D2 social, 0.708 ± 0.051 , $n = 11$ cells, $p = 0.00845$ unpaired t-test); and the magnitude of EPSC OT-LTD is not different in D1 versus D2 MSNs from slices made from isolation conditioned animals (**g-i**) ($p = 0.957$ unpaired t-test). Representative traces are binned from 5 consecutive sweeps taken at times indicated (1 and 2). Summary data are presented as mean $\pm$ s.e.m (* $P < 0.05$).




Supplementary Figure 7. OT receptor (OTR) expressing cells in the NAc. **a**, Diagram illustrating immunolabeling with cell-type specific antibodies in the NAc of OTR-Venus mice. **b**, DARP positive MSNs (blue, left) and OTR-Ven positive cells (green, center) do not co-localize (merge, right). **c**, CHAT positive cholinergic interneurons (blue, left) and OTR-Ven positive cells (green, center) do not co-localize (merge, right). **d**, nNOS positive inhibitory interneurons (blue, left) and OTR-Ven positive cells (green, center) do not co-localize (merge, right). **e**, a subset of PARV positive inhibitory interneurons (blue, left) and OTR-Venus positive cells (green, center) show co-localization (merge, right). **f**, a subset of GFAP positive glial cells (blue, left) and OTR-Ven positive cells (green, center) show co-localization (merge, right). (Scale bars 20 μ m)




Supplementary Figure 8. OT receptor expressing cells that project to the NAc. **a**, Diagram illustrating stereotaxic injection of RbV-TdTomato into the NAc of OTR-Venus mice. **b-m**, high magnification images of cells in the (b) anterior cingulate cortex, ACC; (c) orbitofrontal cortex, OFC; (d) paraventricular nucleus of the hypothalamus, PVN; (e) anterior olfactory nucleus, AON; (f) paraventricular thalamus, PV; (g) basolateral amygdala, BLA; (h) cortex of the amygdala, CoA; (i) ventral hippocampal CA1, vCA1; (j) dorsal Raphe nucleus, dRph; (k) caudal ventral tegmental nucleus, VTA; (l) central amygdala, CeA; and ventral subiculum, vSub that have been retrogradely labeled by RbV-GFP taken up by presynaptic terminals in the NAc (red, left panels) and that express OTR-Venus (green, center panels). Co-localization (merge, right panels) is notably absent in (b) ACC and (c) OFC, but in all other regions (d-m), a subset of cells show clear co-localization (project to the NAc and express OTR-Venus), implicating these neurons as a putative source of presynaptic OTRs in the NAc. (Scale bars 20 μ m).




Supplementary Figure 9. OT does not alter inhibitory postsynaptic currents (IPSCs) recorded from NAc MSNs. Representative traces (**a**), summary time course (**b**) and average post-treatment magnitude comparisons (**c**) reveal absence of significant OT-induced changes in IPSC amplitude (pre 1.023 ± 0.0186 , post 0.962 ± 0.0456 , $n = 11$ cells, $p = 0.557$ paired t-test). Representative traces are binned from 5 consecutive sweeps taken at times indicated (1 and 2). Summary data are presented as mean $\pm$ s.e.m (* $P < 0.05$).




Supplementary Figure 10. Post-hoc confirmation of viral injection sites and transgene expression. **a,b** Localization and expression of (a) AAV-Cre-GFP and (b) RbV-Cre-GFP stereotaxic injections into the NAc. **c,d,e**, Localization and expression of AAV-Cre-GFP stereotaxic injections into the (c) dRph, (d) ACC and (e) vSub. (Nucleus accumbens core, NAcc; nucleus accumbens shell, AcbSh; anterior commissure, aca; caudate putamen a.k.a. dorsal striatum, CPu; dorsal Raphe, dRph; fourth ventricle, 4V; cerebellum, Cb; anterior cingulate cortex, ACC; corpus callosum, CC; lateral ventricle, LV; ventral subiculum, vSub; ventral CA1 region of the hippocampus, vCA1; entorhinal cortex, Ctx; Scale bars 250 μ m)




Supplementary Figure 11. Confirmation of viral tropism for OTR-expressing and NAc-projecting cells. **a**, Diagram illustrating stereotaxic injection of RbV-TdTomato into the NAc of OTR-Venus mice followed by AAV-BFP expression in either dorsal Raphe nucleus, dRph, anterior cingulate cortex, ACC or ventral subiculum, vSub shown in (**b-d**). **b-d**, high magnification images of cells in the (b) dRph (c) ACC or (d) vSub that have been retrogradely labeled by RbV-GFP taken up by presynaptic terminals in the NAc (red, left panels), labeled by local infection with AAV-BFP (blue, center left), and that express OTR-Venus (green, center right panels). Clear co-localization (merge, right panels) between RbV-TdTomato, OTR-Venus and AAV-BFP is evident in (b and d) and co-localization between OTR-Venus and AAV-BFP is evident (c). **e**, Diagram illustrating stereotaxic injection of AAV-BFP into the NAc of OTR-Venus mice or WT mice followed by subsequent immunohistochemistry with anti-Parvalbumin antibody shown in (**f-g**). **f**, Local infection with AAV-BFP (blue, left) in cells that express OTR-Venus (green, center). Co-localization (merge, right) indicates AAV tropism for OTR expressing cells in the NAc. **g**, Local infection with AAV-BFP (blue, left) in cells that express Parvalbumin (red, center). Co-localization (merge, right) indicates AAV tropism for Parvalbumin expressing cells in the NAc. **h**, Diagram illustrating stereotaxic injection of RbV-TdTomato into the NAc of OTR-Venus mice shown in (i). **i**, Local infection with RbV-TdTomato (red, left) in cells that express OTR-Venus (green, center). Co-localization (merge, right) indicates RbV tropism for OTR expressing cells in the NAc. (Scale bars 20 μ m).




Supplementary Figure 12. ACC and vSub OT receptors (OTRs) are not required for sCPP. **a**, Diagram illustrating time course of viral injections into the ACC and vSub for sCPP experiments in **b-e**. **b,c,d** Individual (top) and average (bottom) preference scores indicate that un-injected cOTR KO animals (**b**), cOTR KO animals injected with AAV-Cre-GFP into the ACC (**c**) and cOTR KO animals injected with AAV-Cre-GFP into the vSub (**d**) have increased preference for the social bedding cue after conditioning (un-injected cOTR KO, pre 935 ± 82 , post 1151 ± 68 , $n = 10$, $p = 0.044$ paired t-test; cOTR KO AAV-Cre-GFP ACC, pre 935 ± 78 , post 1160 ± 61 , $n = 12$, $p = 0.034$; cOTR KO AAV-Cre-GFP vSub, pre 907 ± 90 , post 1085 ± 85 , $n = 12$, $p = 0.043$). **e**, Comparisons between un-injected cOTR KO versus cOTR KO animals injected with AAV-Cre-GFP into the ACC or vSub reveals no difference in normalized social preference and subtracted social preference (normalized uninjected 1.250 ± 0.095 , cOTR KO AAV-Cre-GFP ACC 1.362 ± 0.166 , cOTR KO AAV-Cre-GFP vSub 1.271 ± 0.124 , $p = 0.812$, ANOVA; subtracted uninjected 0.212 ± 0.078 , cOTR KO AAV-Cre-GFP ACC 0.251 ± 0.104 , cOTR KO AAV-Cre-GFP vSub 0.199 ± 0.087 , $p = 0.912$, ANOVA). Summary data are presented as mean $\pm$ s.e.m. (* $P < 0.05$).




Supplementary Figure 13. OT receptor-expressing cells in the dRph send serotonergic projections to the NAc. **a**, Diagram illustrating stereotaxic injection of RbV-TdTomato into the NAc of OTR-Venus reporter mice, followed by subsequent immunohistochemistry with anti-tryptophan hydroxylase antibodies to label serotonergic neurons of the dRph. **b,c**, Low magnification (**b**, scale bar 200 μ m) and high magnification (**c**, scale bar 20 μ m) images of neurons in the dRph that send projections to the NAc (red, left), express OTR (green, middle left) and produce 5-HT (blue, middle right). Arrowheads and merged image (right) shows subset of neurons that show colocalization. (dorsal raphe, dRph; fourth ventricle, 4V).



Supplementary Figure 14. Molecular ablation of OTRs in dorsal raphe does not disrupt 5HT1b agonist induced LTD. **a**, Diagram illustrating time course of viral injections into the dRph for LTD experiments in **b-d**. Representative traces (**b**), summary time course (**c**) and average post-treatment magnitude comparisons (**d**) reveal 5HT1b induced-LTD in EPSCs recorded from cOTR animals whose OTRs had been molecularly ablated by AAV-Cre-eGFP dRph injection (dRph-AAV-Cre-eGFP injected cOTR, pre 1.0158 ± 0.0315 , post 0.3566 ± 0.0891 , $n = 5$ cells, $p = 0.0031$ paired t-test). Representative traces are binned from 5 consecutive sweeps taken at times indicated (1 and 2). Summary data are presented as mean $\pm$ s.e.m (* $P < 0.05$).



Supplementary Figure 15. 5HTR1b-A alone does not alter mini EPSC frequency or amplitude. **a**, Representative miniature EPSCs (mEPSCs) recorded in control neurons (purple) and neurons treated with NAS-181 (red, 20 μ M, 10 minutes). **b**, Cumulative probability (top) and average (bottom) mEPSC frequency is not decreased in NAS-treated cells compared to control cells (control 3.31 ± 0.456 , $n = 10$ cells, NAS-181 3.36 ± 0.409 , $n = 10$ cells; $p = 0.9346$ unpaired t-test). **c**, Cumulative probability (top) and average (bottom) mEPSC amplitude is not different in NAS-treated cells compared to control cells (control 16.13 ± 1.152 , $n = 10$ cells, NAS-181 16.90 ± 0.886 , $n = 10$ cells; $p = 0.5826$ unpaired t-test). Summary data are presented as mean $\pm$ s.e.m (* $P < 0.05$).



Supplementary Figure 16. Diagram illustrating model for induction of OT-induced LTD in NAc. OT producing neurons from the PVN release OT into the NAc. Activation of OTRs on presynaptic terminals of 5-HT neurons from the dRph causes the release of 5-HT into the NAc. Activation of 5HT1b receptors on glutamatergic terminals from various brain regions (cortex, amygdala, thalamus) decrease presynaptic function at excitatory synapses onto MSNs.